You are here

P&T News

July 17

But diabetes group tamp down expectations.
Some see the loss of an important, unbiased source of information.
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
The move is considered part of the antiterrorism effort.
An impurity has been found to be carcinogenic.

July 10

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.

July 3

Health plans expected to continue pushing for value-based payment arrangements.
One of the proposed changes makes remote patient monitoring an allowable cost.
European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.
Puts down $700 million to buy nearly 50% of Samsung.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.

June 26

Sensor alerts adults with diabetes of high or low glucose levels via smartphone or tablet
Gottlieb spoke at the NCCN Policy Summit on the role of data analytics in drug trials
Epidiolex is indicated for rare, severe forms of epilepsy
Patients as young as 7 years of age may now use the device for their type-1 diabetes

Pages